Stock Analiz

Korsana Biosciences, Inc. (KRSA) financials: revenue, earnings and cash flow

Fiscal 2018–2025 · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$4M, a net margin of -170.1%; the best year in this period was 2024 with -$3M.

The diluted share count rose 132% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $5M20192020: $2M20202021: $4M20212022: $29700020222023: $020232024: $2M20242025: $2M2025$2M
Net income
2018: -$115M20182019: -$123M20192020: -$78M20202021: -$52M20212022: -$44M20222023: -$5M20232024: -$3M20242025: -$4M2025-$4M
Free cash flow
2018: -$101M20182019: -$109M20192020: -$74M20202021: -$37M20212022: -$41M2022-$41M
EPS (diluted)
2018: $-0.0120182019: $-5.9920192020: $-3.4120202021: $-1.7620212022: $-1.3520222023: $-0.1520232024: $-0.0820242025: $-0.072025$-0.07

Income statement

Fiscal year20252024202320222021202020192018
Revenue$2M$2M$0$297000$4M$2M$5M—
Gross profit————————
Operating income-$5M-$4M-$13M-$19M-$55M-$81M-$125M-$115M
Net income-$4M-$3M-$5M-$44M-$52M-$78M-$123M-$115M
EPS (diluted)$-0.07$-0.08$-0.15$-1.35$-1.76$-3.41$-5.99$-0.01
R&D$959000$286000$2M$6M$38M$56M$95M$88M
Revenue growth+3.7%—−100.0%−92.5%+71.7%−49.1%——

Cash flow

Fiscal year20252024202320222021202020192018
Operating cash flow-$3M-$4M-$21M-$41M-$37M-$72M-$102M-$98M
Capital spending———$0-$7000-$2M-$7M-$3M
Free cash flow———-$41M-$37M-$74M-$109M-$101M
Dividends paid$0$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$441000$625000$1M$6M$10M$15M$20M$12M

Balance sheet

Fiscal year20252024202320222021202020192018
Cash$3M$3M$8M$13M$54M$54M$95M—
Debt———$4M$4M$46M$74M—
Equity$9M$9M$11M$10M$48M$59M$98M-$10M
Total assets$10M$10M$13M$18M$59M$115M$186M$7M
Shares (diluted)48M38M35M33M29M23M21M21M

Margins and returns

Fiscal year20252024202320222021202020192018
Gross margin————————
Operating margin-239.8%-181.4%—-6242.4%-1400.2%-3539.4%-2774.3%—
Net margin-170.1%-152.8%—-14841.1%-1310.2%-3388.6%-2729.3%—
FCF margin———-13673.7%-926.5%-3223.6%-2420.8%—
ROIC-54.7%-41.0%-114.7%-132.9%-106.7%-77.2%-72.8%—
ROE-38.8%-34.5%-46.6%-421.7%-107.0%-130.8%-125.9%1103.4%

Frequently asked questions

What is Korsana Biosciences’s annual revenue?

$2M in fiscal 2025.

How much profit does Korsana Biosciences make?

Net income was -$4M in fiscal 2025 (net margin -170.1%).

Is Korsana Biosciences’s revenue growing?

Yes: revenue rose 3.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.